ArticleAnalytical chemistry2024
Gold Nanoparticle-Decorated Catalytic Micromotor-Based Aptassay for Rapid Electrochemical Label-Free Amyloid-β42 Oligomer Determination in Clinical Samples from Alzheimer's Patients.
Article in Analytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Aptamer-Based Platforms for Human Aging Biomarkers: Multiplexed Proteomics, Biosensors and Translational Perspectives.International journal of molecular sciences · 2026Review
- Progress in (Photo)electrochemical Biosensors for the Detection of Amyloid-Beta Oligomer.Biosensors · 2026Review
- Advancements in Nanomaterial-Based Biosensors for Neuropsychiatric and Neurodegenerative Diagnostics: From Biomarker Discovery to Clinical Translation.Biosensors · 2026Review
- Recent advances in microfluidic technologies for the detection of Alzheimer's disease biomarkers: toward point-of-care neurodiagnostic.Mikrochimica acta · 2026Review
- Motorized DNAzymes Drive Enhanced Electrochemical Biosensing for Rapid Bacterial Detection.Small methods · 2026Article
- Carbon Nanomaterial-Based Electrochemical Biosensors for Alzheimer's Disease Biomarkers: Progress, Challenges, and Future Perspectives.Biosensors · 2025Review
- ZIF-8 Microswimmers Self-Fast Dynamic Destruction in Microliter Volumes of Cerebrospinal Fluid Samples: Toward a Selective Assessment of Amyloidosis.Analytical chemistry · 2025Article
- Technology Roadmap of Micro/Nanorobots.ACS nano · 2025Review
- Micromotors Meet Collective (Bio)sensing: The Asset Behind the Assay.Analytical chemistry · 2025Review
- Bioelectroanalytical Technologies for Advancing the Frontiers To Democratize Personalized Desired Health.Analytical chemistry · 2025Review
- Nanomaterials in targeting amyloid-β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy.Beilstein journal of nanotechnology · 2025Review
- Nanoparticle-Based Drug Delivery Systems Enhance Treatment of Cognitive Defects.International journal of nanomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Micromotor (MM) technology offers a valuable and smart on-the-move biosensing microscale approach in clinical settings where sample availability is scarce in the case of Alzheimer's disease (AD). Soluble amyloid-β protein oligomers (AβO) (mainly AβO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.